The ischemic biomarker Heart-type Fatty Acid Binding Protein [H-FABP] can substantially improve the detection of high risk patients when Troponin-negative, even when a high sensitivity assay is used, a new publication has shown. In the June edition of JACC, Professor Alistair Hall and colleagues from the University of Leeds, UK, prospectively studied a cohort of 1080 consecutive patients admitted to hospital with suspected ACS and compared the H-FABP assay (Randox Laboratories) with the high sensitivity Ultra-TnI assay (Siemens Healthcare Diagnostics).